Your browser doesn't support javascript.
loading
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson, Kerry A; Baeten, Jared M; Mugo, Nelly R; Bekker, Linda-Gail; Celum, Connie L; Heffron, Renee.
Afiliación
  • Thomson KA; aDepartment of Global Health bDepartment of Epidemiology cDepartment of Medicine, University of Washington, Seattle, USA dSexual Reproductive Adolescent and Child Health Program, Kenya Medical Research Institute, Nairobi, Kenya eThe Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Curr Opin HIV AIDS ; 11(1): 18-26, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26417954
PURPOSE OF REVIEW: Despite tremendous promise as a female-controlled HIV prevention strategy, implementation of preexposure prophylaxis (PrEP) among women has been limited, in part because of disparate efficacy results from randomized trials in this population. This review synthesizes existing evidence regarding PrEP efficacy for preventing HIV infection in women and considerations for delivering PrEP to women. RECENT FINDINGS: In three efficacy trials, conducted among men and women, tenofovir-based oral PrEP reduced HIV acquisition in subgroups of women by 49-79% in intent-to-treat analyses, and by >85% when accounting for PrEP adherence. Two trials did not demonstrate an HIV prevention benefit from PrEP in women, but substantial evidence indicates those results were compromised by very low adherence to the study medication. Qualitative research has identified risk perception, stigma, and aspects of clinical trial participation as influencing adherence to study medication. Pharmacokinetic studies provide supporting evidence that PrEP offers HIV protection in women who are adherent to the medication. SUMMARY: Tenofovir-based daily oral PrEP prevents HIV acquisition in women. Offering PrEP as an HIV prevention option for women at high risk of HIV acquisition is a public health imperative and opportunities to evaluate implementation strategies for PrEP for women are needed.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Transmisión de Enfermedad Infecciosa / Quimioprevención / Fármacos Anti-VIH / Cumplimiento de la Medicación / Profilaxis Pre-Exposición / Tenofovir Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Female / Humans / Male Idioma: En Revista: Curr Opin HIV AIDS Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2016 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Transmisión de Enfermedad Infecciosa / Quimioprevención / Fármacos Anti-VIH / Cumplimiento de la Medicación / Profilaxis Pre-Exposición / Tenofovir Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Límite: Female / Humans / Male Idioma: En Revista: Curr Opin HIV AIDS Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2016 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Estados Unidos